Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - iron(iii)-hydroxide polymaltose complex 357mg eqv iron (iii) - tablet, film coated - iron(iii)-hydroxide polymaltose complex 357mg eqv iron (iii) 100mg

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - ferric carboxymaltose 180 mg eqv iron - injection, solution - 50mg - ferric carboxymaltose 180 mg eqv iron 50 mg/ml

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - hydroxide polymaltose complex eqv iron - syrup - 10mg/ml - hydroxide polymaltose complex eqv iron 50mg/5ml

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - iron hydroxide polymaltose eqv iron - solution - 50 mg/ml - iron hydroxide polymaltose eqv iron 50 mg/ml

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - etamsylate - capsule - 500mg

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - difelikefalin acetate eqv difelikefalin - injection, solution - difelikefalin acetate eqv difelikefalin 0.05mg/ ml

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - iron eqv iron sucrose - injection - 100 mg/5 ml - iron eqv iron sucrose 100 mg/5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - iron polymaltose -

Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ulipristal acetate -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron sucrose 540 mg/ml equivalent to iron 20 mg/ml - solution for injection - 20 mg/ml - active: iron sucrose 540 mg/ml equivalent to iron 20 mg/ml excipient: water for injection - venofer is indicated for the treatment of iron deficiency in the following indications: · where there is a clinical need for a rapid iron supply, · in patients who cannot tolerate oral iron therapy or who are non-compliant, · in active inflammatory bowel disease where oral iron preparations are ineffective.